Drug/Lab test interactions:

Since leuprotide suppresses the pituitary -gonadal system, diagnostic tests o f pituitary gonodotropic and gonadol functions during treatment and upto 12 weeks after discontinuing depot may be misleading.

Advanced prostatic cancer

ECG changes, high blood pressure, edema, Insomnia, sleep disorders, Pain, headache, Dizziness, light headedness, Hot flushes, Nausea, vomiting, Bone pain, Urinary frequency/urgency/ disorders hematuria, Urinary tract infection, Anemia, Asthenia

Pregnancy, lactation.

Special precautions:

Flare phenomenon, to reduce risk of flare in initial therapy an anti-androgen may be administered 3 days before therapy and continued for 2-3 weeks Patients at risk of ureteric obstruction, Metastatic vertbral lesions and spinal compression Monitor in first few weeks and consider antiandrogens Bone density changes, monitoring patients with prostatic cancer.

Indications:

Advanced prostatic cancer

Dosage:

Injection- 1mg SC daily.

Use the syringes included in the kit

1. Do not discontinue medication except on advise of physician

2. Patients should use nonhormonal methods of contraception. Advise patients to see physician , if they believe that they may be pregnant

3. If the patient becomes pregnant during treatment, discontinue the drug and appraise the patient of the potential risk to the fetus.

Pharmacology:

Leuprolide an LH-RH agonist, is a synthetic nonapeptide analog of naturally occurring gonadotropin releasing hormone with greater potency than the natural hormone. It occupies pitutary receptors and desensitizes them, thus it inhibits gonodatropin secretion when given continously and in therapeutic doses.

Pregnancy:

Leuprolide is contraindicated in women who are or who may become pregnant while receiving the drug.

Lactation:

Do not use during nursing